| Antibody (BAN50)-coated Plate | 1plate, 96 well ( 8 x 12) |
|---|---|
| Standard Solution (10 nM) | 100 µL x 1 |
| Buffer | 60 mL x 1 |
| Biotin-conjugated Antibody (BAN50) Solution | 100 µL x 1 |
| Peroxidase-conjugated Streptavidin Solution | 100 µL x 1 |
| Luminescent Reagent 1 | 6 mL x 1 |
| Luminescent Reagent 2 | 6 mL x 1 |
| Wash Solution (10x) | 100 mL x 1 |
| Plate Seal | 3 sheets |
This sandwich ELISA method uses anti-Aβ antibody (BAN50) for both capturing and detecting the target. The antibody rarely reacts with 1-8-mers; instead, it is specific to ≥ 9-mer Aβ oligomers3) 4).
| Standard curve range | 0.410 pM - 100 pM※1 |
|---|---|
| Reactive Aβ oligomers | ≧ 9-mer Aβ oligomers |
| Samples※2 | Human cerebrospinal fluid, in vitro Aβ oligomer |
| Cross-reactivity | Human |
| Sample volume | 25 µL(for 4 times dilution) |
| Assay time | 4.5 hours |
| Detection method | Luminescence method※3 |
※1: Calculated on the basis of 16-mer MAP peptide.
※2: Plasma and serum samples are not recommended for use.
※3: A luminescence plate reader is required for the assay
Aβ1-42 peptide was incubated overnight at 4°C and was separated into those that are
The signal was weak for Fraction B containing ≤ 8-mers (< 30kDa), while the signal was strong for Fraction A containing ≥ 9-mers (≥ 30 kDa).
Aβ oligomers in the CSF derived from patients with Alzheimer’s disease (AD) and without dementia (control) were measured using our ELISA kit and a competitor’s kit.
| MMSE score ※4 | Our Aβ oligomer kit (pM) | Competitor’s Aβ oligomer kit (pg/mL) | |
|---|---|---|---|
| Control 1 | － | 0.98 | N.D. |
| Control 2 | － | 1.99 | 33 |
| Control 3 | － | 1.69 | 37 |
| Control 4 | － | 4.59 | 88 |
| Control 5 | － | 1.73 | 55 |
| AD1 | 20 | 4.40 | 90 |
| AD2 | 20 | 4.11 | 113 |
| AD3 | 26 | 4.95 | 100 |
| AD4 | 24 | 5.84 | 78 |
| AD5 | 15 | 5.74 | 105 |
※4: MMSE (Mini-Mental State Examination) score:
30-28: Normal
27-24: Suspected of mild cognitive impairment
≤ 23: Suspected of dementia
There was a significant difference in the measurements between the control and AD patients. Compared to the competitor’s product, the difference between the groups was larger when our product was used.
| Outline | Recently, amyloid beta oligomer is focused as a cause of Alzheimer's disease. Amyloid beta oligomer is a soluble aggregate by polymerized of Amyloid beta monomers, and it impairs synaptic function of neurons. Amyloid beta oligomer has several types, low molecular Amyloid beta oligomers(Low-n oligomer) and high molecular Amyloid beta oligomers (ADDL, Abeta*56 and proto-fibril). This item is an ELISA kit that can specifically measure high molecular Amyloid beta oligomers. Standard curve range:0.410-100 pM Reactive Amyloid beta oligomer: over 9mer Amyloid beta oligomer Sample:Cerebrospinal fluid, In vitro Amyloid beta oligomer Cross-reactivity:Human Sample volume: 25uL (4 times dilution) Assay time: 4.5 hours Detection method:Luminescence method Reference Forner, S., et al.: Sci. Rep., 9, 1, 15936(2019). |
|---|